19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Models, mechanisms and clinical evidence for cancer dormancy.

      Nature reviews. Cancer

      Animals, Disease Progression, Drug Resistance, Neoplasm, Epigenesis, Genetic, Humans, Mice, Mice, Inbred Strains, Mice, Transgenic, Models, Biological, Neoplasm Invasiveness, physiopathology, Neoplasm Metastasis, Neoplasm Proteins, physiology, Neoplasm Recurrence, Local, Neoplasm, Residual, Neoplasms, blood supply, genetics, immunology, pathology, Neovascularization, Pathologic, Time Factors, Tumor Burden, Tumor Escape

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades. This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic. Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease. Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance. The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.

          Related collections

          Author and article information

          Journal
          17957189
          2519109
          10.1038/nrc2256

          Comments

          Comment on this article